Apixaban Dose Adjustment in Elderly Patients
Dose Adjustment Criteria for Apixaban
- The European Society of Cardiology recommends a standard dose of apixaban of 5 mg twice daily for most patients with atrial fibrillation, but a reduced dose of 2.5 mg twice daily is recommended when at least two of the following criteria are met: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 μmol/L) 1, 2, 3
- The American College of Cardiology suggests that a single criterion alone does not warrant dose reduction, as patients with only one criterion show consistent benefits with the standard 5 mg twice daily dose is not applicable due to lack of reference, however, age ≥80 years is a criterion for dose reduction 4
- Body weight ≤60 kg is also a criterion for dose reduction 5
Renal Function Considerations
- Apixaban has the lowest renal clearance (27%) among direct oral anticoagulants (DOACs), making it potentially preferable in elderly patients with renal impairment, according to the American Heart Association 2, 6
- For severe renal impairment, the European Society of Cardiology recommends the following doses: CrCl 15-29 mL/min: 2.5 mg twice daily, and CrCl <15 mL/min: generally not recommended, though some guidelines suggest considering 2.5 mg twice daily 2, 5, 3
Evidence Supporting Dose Adjustment
- The ARISTOTLE trial demonstrated that apixaban significantly reduced stroke or systemic embolism by 21% compared with warfarin, with a 31% reduction in major bleeding, as reported by the European Heart Journal 1
Special Considerations in Elderly Patients
- Elderly patients are at higher risk for both thromboembolic and bleeding events, according to the European Society of Cardiology 7, 3
- Apixaban has demonstrated a favorable safety profile in elderly patients compared to warfarin, with less intracranial hemorrhage, as reported by the European Heart Journal 1, 3
- Concomitant medications that affect bleeding risk (antiplatelets, NSAIDs, SSRIs) should be avoided when possible, as suggested by the American Heart Association 7, 8
Monitoring Recommendations
- Baseline and regular assessment of renal function is essential, according to the European Society of Cardiology 6, 3
- For elderly patients with moderate renal impairment, assess renal function 2-3 times per year, as recommended by the American College of Cardiology 6, 4
- No routine coagulation monitoring is required for apixaban, as reported by the European Heart Journal 1, 6